State of New Jersey Common Pension Fund D Has $2.23 Million Holdings in Masimo Co. (NASDAQ:MASI)

State of New Jersey Common Pension Fund D boosted its holdings in shares of Masimo Co. (NASDAQ:MASI) by 1.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,736 shares of the medical equipment provider’s stock after purchasing an additional 194 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Masimo were worth $2,231,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Farallon Capital Management LLC increased its stake in shares of Masimo by 13.6% in the first quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock valued at $218,742,000 after buying an additional 177,914 shares in the last quarter. Thrivent Financial for Lutherans increased its position in Masimo by 42.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock valued at $153,314,000 after acquiring an additional 360,497 shares in the last quarter. Point72 Asset Management L.P. raised its stake in shares of Masimo by 107.8% in the second quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider’s stock worth $85,347,000 after acquiring an additional 351,523 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Masimo by 45.9% during the second quarter. Dimensional Fund Advisors LP now owns 525,594 shares of the medical equipment provider’s stock worth $66,201,000 after purchasing an additional 165,257 shares in the last quarter. Finally, Bamco Inc. NY bought a new stake in shares of Masimo during the first quarter valued at approximately $50,781,000. Institutional investors own 85.96% of the company’s stock.

Wall Street Analysts Forecast Growth

MASI has been the topic of several research reports. Piper Sandler upped their price objective on Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. BTIG Research upped their price target on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research report on Wednesday, November 6th. Wells Fargo & Company raised their target price on shares of Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, Raymond James raised shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target for the company in a research note on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Masimo has an average rating of “Moderate Buy” and a consensus price target of $163.67.

Masimo Stock Performance

Shares of NASDAQ:MASI opened at $160.15 on Friday. The firm’s 50 day simple moving average is $136.27 and its 200 day simple moving average is $126.54. Masimo Co. has a fifty-two week low of $89.18 and a fifty-two week high of $173.90. The company has a market capitalization of $8.57 billion, a price-to-earnings ratio of 110.38 and a beta of 0.97. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. During the same period last year, the firm posted $0.63 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Masimo Co. will post 4.04 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.